All Title Author
Keywords Abstract


Sequential and Dual Inhibition of Pleiotropic Targets in Cancer—A Novel Strategy to Sensitize Tumor Cells to Targeted Therapies and Overcome Resistance

DOI: 10.4236/jct.2019.102013, PP. 166-177

Keywords: Targeted Therapies, Multitargeted Epigenetic Therapy, Oncogenic Addiction, Tumor Resistance, Tyrosine Kinase

Full-Text   Cite this paper   Add to My Lib

Abstract:

In this paper we discuss the rationale of applying a “sequential” targeted therapy with a specific application in clinical practice, given our understanding of cancer heterogenous and dynamic biology. We explore the advantages of “single inhibition” to combinational therapies and dual inhibition on key pathways, as well as a multi-step approach to use “oncological addiction” and “oncogenic shock” as a suicide plan for cancer. We specifically explain how the downstream targets can be used to “create” feedback loops in an advantage for creating actionable targets in upstream signaling molecules. We apply this hypothesis in the clinical setting, with superior outcomes shown in a series of case studies. We conclude that “sequential and dual inhibition” can be considered a meaningful approach to checkmate the tumor, with minimum chance of tumor resistance. We recommend further clinical studies to generate further hypotheses based on each actionable target.

References

[1]  Tuna, M. and Amos, C.I. (2012) Activating Mutations and Targeted Therapy in Cancer. Mutations in Human Genetic Disease, Chapter 14, 273-292.
https://doi.org/10.5772/48701
[2]  Lu, J.-J., Pan, W., Hu, Y.-J. and Wang, Y.-T. (2012) Multi-Target Drugs: The Trend of Drug Research and Development. PLoS ONE, 7, e0040262.
https://doi.org/10.1371/journal.pone.0040262
[3]  Chia, S., Gandhi, S., Joy, A., Edwards, S., Gorr, M., Hopkins, S. and Dent, S. (2015) Novel Agents and Associated Toxicities of Inhibitors of the pi3k/Akt/mtor Pathway for the Treatment of Breast Cancer. Current Oncology, 22, 33.
https://doi.org/10.3747/co.22.2393
[4]  https://am.asco.org/exploring-pathway-pi3k-pathway-fact-sheet
[5]  Stewart, E.L., Tan, S.Z., Liu, G. and Tsao, M.S. (2015) Known and Putative Mechanisms of Resistance to EGFR Targeted Therapies in NSCLC Patients with EGFR Mutations—A Review. Translational Lung Cancer Research, 4, 67-81.
[6]  Cortot, A.B. and Janne, P.A. (2014) Molecular Mechanisms of Resistance in Epidermal Growth Factor Receptor-Mutant Lung Adenocarcinomas. European Respiratory Review, 23, 356-366.
https://doi.org/10.1183/09059180.00004614
[7]  Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., Bencardino, K., Cercek, A., Chen, C.T., Veronese, S., Zanon, C., Sartore-Bianchi, A., Gambacorta, M., Gallicchio, M., Vakiani, E., Boscaro, V., Medico, E., Weiser, M., Siena, S., Di Nicolantonio, F., Solit, D. and Bardelli, A. (2012) Emergence of KRAS Mutations and Acquired Resistance to Anti-EGFR Therapy in Colorectal Cancer. Nature, 486, 532-536.
https://doi.org/10.1038/nature11156
[8]  Luque-Cabal, M., García-Teijido, P., Fernández-Pérez, Y., Sánchez-Lorenzo, L. and Palacio-Vázquez, I. (2016) Mechanisms behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It. Clinical Medicine Insights. Oncology, 10, 21-30.
https://doi.org/10.4137/CMO.S34537
[9]  Villanueva, J., Vultur, A. and Herlyn, M. (2011) Resistance to BRAF Inhibitors: Unraveling Mechanisms and Future Treatment Options. Cancer Research, 71, 7137-7140.
https://doi.org/10.1158/0008-5472.CAN-11-1243
[10]  Yardley, D.A. (2013) Drug Resistance and the Role of Combination Chemotherapy in Improving Patient Outcomes. International Journal of Breast Cancer, 2013, 1-15.
https://doi.org/10.1155/2013/137414
[11]  Nagaraja, A.K. and Bass, A.J. (2015) Hitting the Target in BRAF-Mutant Colorectal Cancer. Journal of Clinical Oncology, 33, 3990-3992.
https://doi.org/10.1200/JCO.2015.63.7793
[12]  Tolcher, A.W., Bendell, J.C., Papadopoulos, K.P. and Infante, J.R. (2014) A Phase IB Trial of the Oral MEK Inhibitor Trametinib (GSK1120212) in Combination with Everolimus in Patients with Advanced Solid Tumors. Annals of Oncology, 26, 58-64.
https://doi.org/10.1093/annonc/mdu482
[13]  Chandarlapaty, S., Sawai, A., et al. (2011) AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity. Cancer Cell, 19, 58-71.
[14]  Tao, J.J., Castel, P., Radosevic-Robin, N., Elkabets, M., Baselga, J. and Scaltriti, M. (2014) Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast Cancer. Science Signaling, 7.
[15]  Torti, D. and Trusolino, L. (2011) Oncogene Addiction as a Foundational Rationale for Targeted Anti-Cancer Therapy: Promises and Perils. EMBO Molecular Medicine, 3, 623-636.
https://doi.org/10.1002/emmm.201100176

Full-Text

comments powered by Disqus

Contact Us

service@oalib.com

QQ:3279437679

微信:OALib Journal